NEOMED-LABS and Public Health England’s (PHE) National Infection Service have entered a strategic partnership aimed at improving global human health. This partnership is focused on vaccine projects with the objective of jointly developing new preclinical and clinical assays to support R&D and clinical biopharmaceutical teams in fields such as infectious disease vaccines and immunotherapies.

NEOMED-LABS and PHE’s Vaccine Research Groups have engaged in a collaboration targeting Influenza and Zika, assessing concomitant vaccine responses and initiating a minimum of three additional collaborative projects before the end of 2019. The main objective is to build a universal program to support prophylactic and therapeutic vaccine development from preclinical to post-licensure in different fields, including seasonal/pandemic, pediatric and emergent diseases.

“We are thrilled at the prospects opened by this strategic partnership with a venerable and admired institution and the initiation of our collaboration with a team led by such a recognized key opinion leader in the vaccine field. This partnership was made in recognition of PHE’s continued advancement of vaccine research for the development of counter measures against emerging and re-emerging diseases. It will give the opportunity for NEOMED-LABS to have a collaborator in Europe and to further expand its offerings, capabilities and coverage,” said Dr Benoit Bouche, NEOMED-LABS President and Chief Executive Officer. 

“We have great synergy and complementarity, in terms of our expertise. The ability of NEOMED-LABS to provide high-throughput testing expertise alongside PHE’s capabilities in assay development and validation will advance research and development of these needed vaccines to impact human health at a global level,” said Dr Bassam Hallis.